Linagliptin

IUPAC name:

8-[(3R)-3-aminopiperidin-1-yl]-7-but-2-ynyl-3-methyl-1-[(4-methylquinazolin-2-yl)methyl]purine-2,6-dione

CAS No.

668270-12-0

Molecular Weight:

472.5 g.mol−1

Molecular Formula:

C25H28N8O2

Granule:

Mechanism Of Action:

Linagliptin is a competitive, reversible DPP-4 inhibitor. Inhibition of this enzyme slows the breakdown of GLP-1 and glucose-dependant insulinotropic polypeptide (GIP). GLP-1 and GIP stimulate the release of insulin from beta cells in the pancreas while inhibiting release of glucagon from pancreatic beta cells. These effects together reduce the breakdown of glycogen in the liver and increase insulin release in response to glucose.

Indication:

Linagliptin is used as monotherapy, or in combination with other antidiabetic medicines including insulin, for treatment of type 2 diabetes.

information

Category: Anti-Diabetic

January 21, 2024

Desloratadine

Anti-Histamine

Cas No: 100643-71-8

Mechanism Of Action: Desloratadine is a non-sedating, long-acting antihistamine that selectively blocks peripheral histamine H1-receptors. It is the major active metabolite of loratadine and works

Voriconazole

Anti-Microbial

Cas No: 137234-62-9

Mechanism Of Action: Voriconazole is a triazole antifungal agent that works by inhibiting the fungal cytochrome P450 enzyme 14-alpha-lanosterol demethylase1. This enzyme is crucial for

Enoxaparin Sodium

Cardiovascular

Cas No: 679809-58-6

Mechanism Of Action: Enoxaparin, a low molecular weight heparin (LMWH), works primarily by activating antithrombin III, which in turn inhibits factor Xa and IIa (thrombin).

Tirzapatide

Anti-Diabetic

Cas No: 2023788-19-2

Mechanism Of Action : Tirzepatide is a dual agonist of the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. This means it mimics the

Lenvatinib Mesylate

Oncology

Cas No: 857890-39-2

Mechanism Of Action: Lenvatinib is classified as a receptor tyrosine kinase (RTK) inhibitor that effectively suppresses the kinase activities of vascular endothelial growth factor (VEGF)

TRAMETINIB DIMETHYL SULFOXIDE

Oncology

Cas No: 1187431-43-1

Mechanism Of Action: Trametinib is identified as a reversible and remarkably selective allosteric inhibitor of MEK1 and MEK2. Through its high-affinity binding to unphosphorylated MEK1